Pilot Study of Extracorporeal Removal of Soluble Fms-Like Tyrosine Kinase 1 in Preeclampsia
Pilot Study of Extracorporeal Removal of Soluble Fms-Like Tyrosine Kinase 1 in Preeclampsia
复制标题
DOI：
10.1161/circulationaha.111.034793
复制
发表时间：
2011-08-23
期刊：
影响因子：
37.8
通讯作者：
Benzing, Thomas
中科院分区：
文献类型：
--
作者：
Thadhani, Ravi;Kisner, Tuelay;Benzing, Thomas
背景：目前尚不存在稳定先兆子痫临床表现和延长妊娠的靶向治疗方法。可溶性FMS样酪氨酸激酶1(sFlt-1)是血管内皮生长因子受体1的选择性剪接变体，在实验模型中诱导子痫前期样表型，并在人类先兆子痫中以高水平循环。去除sflt-1可能使早产妇女受益(
Background-Targeted therapies to stabilize the clinical manifestations and prolong pregnancy in preeclampsia do not exist. Soluble fms-like tyrosine kinase 1 (sFlt-1), an alternatively spliced variant of the vascular endothelial growth factor receptor 1, induces a preeclampsia-like phenotype in experimental models and circulates at elevated levels in human preeclampsia. Removing sFlt-1 may benefit women with very preterm (